Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
Send Cancel

RVC study offers hope for osteoporosis sufferers
An estimated 500,000 people are hospitalised every year for fractures owing to osteoporosis.
Researchers present NaQuinate treatment found to prevent bone loss.

Researchers at the Royal Veterinary College (RVC) have highlighted a promising new treatment for people living with skeletal disorders.

Scientists say the treatment - NaQuinate - presented today (11 September) at the American Society of Bone and Mineral Research (ASBMR), could be used to manage osteoporosis, a debilitating condition that affects more than three million people in the UK.

NaQuinate is a naturally occurring metabolite of vitamin K. Previous studies have shown that it can protect against the loss in bone quality that occurs in ovariectomy in mouse and rat models.

In this new study, NaQuinate was also shown to significantly synergise with mechanical loading in targeted regions of cortical bone. The treatment is currently in Phase I clinical trials to establish its safety and efficacy as a treatment for post-menopausal women with osteoporosis.

Professor Andrew Pitsillides, Professor of Skeletal Dynamics at the RVC, said: “There are three main ways to maintain bone quality and strength to resist fracture: stop bone loss, build mass and enhance the topographical changes to optimise and enhance weight-bearing roles. It may be that NaQuinate can achieve a balance of all three to treat osteoporosis and better maintain healthy ageing.”

An estimated 500,000 people are hospitalised every year for broken bones owing to osteoporosis. The condition causes a significant social and economic burden, with breaks often leading to a downward spiral of disability, loss of independence and increased mortality.

Prof Pitsillides added: “At the RVC we recognise the importance of a collaborative ‘One Health’ approach which operates at the cutting edge of veterinary and human medicine, and this research could pave the way for a novel treatment for this common and debilitating condition.”

The study was developed in collaboration between the Skeletal Biology group at the RVC and biotechnology company Haoma Medica.

Become a member or log in to add this story to your CPD history

Defra extends applications to Zoo Animals Fund

News Story 1
 Defra has extended the deadline for applications for the 100 Million Zoo Animals Fund until 26 February 2021.

Launched in June 2020, the fund provides financial support for zoos and aquariums that have experienced a drop in income caused by the coronavirus pandemic. Grants of up to 730,000 are available, which can be used to pay for essential costs and maintenance, including veterinary care, medicines, animal feed and staffing.

More information about the fund and details of how to apply can be found here

Click here for more...
News Shorts
APHA confirms eighth case of highly pathogenic avian influenza in England

The Animal & Plant Health Agency (APHA) has identified an eighth case of highly pathogenic avian influenza (HPAI) H5N8 in poultry in England.

Confirmed on Tuesday (15 December), the outbreak was found in captive birds and poultry at a premises near Willington, South Derbyshire. A 3km Protection Zone and a 10km Surveillance Zone have been placed around the infected premises to limit the risk of the disease spreading.

Further information about the outbreaks and the latest government advice can be found at